

26. The method of claim 16 wherein the HER2 antibody is pertuzumab.

27. A method for extending time to disease progression (TTP) or survival in breast cancer patients comprising: (a) administering pertuzumab to the patients as a loading dose of 840 mg followed by fixed doses of about 420 mg of the pertuzumab every three weeks and (b) measuring TTP or survival to confirm it is extended in the patients.

28. The method of claim 27 which extends TTP.

29. The method of claim 27 which extends survival. 10

30. The method of claim 27 wherein the patients have metastatic breast cancer.

31. The method of claim 27 wherein the cancer displays HER2 activation.

32. The method of claim 31 wherein the cancer displays 15 amplified or overexpressed HER2.

33. The method of claim 27 comprising administering a second therapeutic agent to the patients.

34. The method of claim 33 wherein the second therapeutic agent comprises trastuzumab. 20

* * * * *